ECM
LUMO

Endurant Capital Management’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Endurant Capital Management’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-4,011
Closed -$367K – 95
2017
Q3 		$367K Sell
4,011
-5,389
-57% -$413K 0.11% 83
2017
Q2 		$622K Buy
9,400
+2,795
+42% +$346K 0.18% 80
2017
Q1 		$1.43M Buy
+6,605
New +$943K 0.46% 57
2016
Q4 		– Sell
-3,310
Closed -$447K – 91
2016
Q3 		$447K Sell
3,310
-3,633
-52% -$361K 0.17% 78
2016
Q2 		$704K Buy
+6,943
New +$861K 0.24% 66

Other funds holding LUMO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Endurant Capital Management's LUMO Position: Q4 2017 in Review

Endurant Capital Management sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q4 2017, closing a stake of 4,011 shares — an estimated $367K sold.

Endurant Capital Management first reported a position in LUMO in Q2 2016 and held it in 5 quarters. The position peaked at $1.43M in Q1 2017. 130 funds tracked by Wall St. Rank hold LUMO as of Q4 2017.

  • Endurant Capital Management reported no remaining Lumos Pharma, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Endurant Capital Management sold 4,011 Lumos Pharma, Inc. Common Stock shares in Q4 2017, an estimated $367K.
  • Endurant Capital Management first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2016 and held it in 5 quarters.
  • Endurant Capital Management's Lumos Pharma, Inc. Common Stock position peaked at $1.43M in Q1 2017.
  • 130 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q4 2017.

Based on Endurant Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.